Glenmark Pharmaceuticals Ltd Share Price Target 2024, 2025 to 2030

Glenmark Pharmaceuticals Ltd, founded in 1977 by Gracias Saldanha and headquartered in Mumbai, India, is a global, research-driven pharmaceutical company. Initially focused on generic drugs and active pharmaceutical ingredients, Glenmark has grown its operations to over 80 countries. The company has diversified its product portfolio to include branded, generic, and over-the-counter (OTC) medications, with a particular emphasis on therapeutic areas such as respiratory, dermatology, and oncology.

Glenmark is committed to innovation, supported by four research and development centers and ten manufacturing facilities across five continents. The company has a strong pipeline of new chemical entities (NCEs) and biosimilars in various clinical development stages. In January 2024, Glenmark and its subsidiary, Ichnos Sciences Inc., launched the Ichnos Glenmark Innovation (IGI) collaboration to accelerate the development of innovative cancer treatments, focusing on multiple myeloma, acute myeloid leukemia, and solid tumors.

Glenmark Pharmaceuticals Sees Net Profit Soar Over 200% in Q1 FY25; Revenue Grows 7%

• Net Profit Increase: Glenmark Pharmaceuticals Ltd reported a significant increase in consolidated net profit to ₹340.2 crore for Q1 FY25, more than doubling from ₹37.7 crore in the same quarter of FY24.
• Profit Before Exceptional Items and Taxes: The company’s profit before exceptional items and taxes soared to ₹462 crore, up from ₹203 crore year-over-year. This increase occurred despite a ₹52.02 crore one-time charge related to repairs at manufacturing facilities.
• Revenue Growth: Consolidated revenue from operations grew by 6.9%, reaching ₹3,244.2 crore compared to ₹3,036 crore in Q1 FY24.
• EBITDA Performance: EBITDA for Q1 FY25 surged by 34.5% to ₹588.3 crore, with the EBITDA margin improving to 18.1% from 14.4% in the same quarter of the previous fiscal year.
• Formulation Sales in India: Sales from the formulation business in India increased by 11.9%, totaling ₹1,196.2 crore versus ₹1,069.3 crore in Q1 FY24.
• Operating Expenses: The operating expenses saw a one-time charge of ₹52.02 crore in the previous fiscal year, impacting comparability but not affecting the overall positive trend in financial performance.
• EBITDA Margin Improvement: The EBITDA margin improved to 18.1%, reflecting enhanced operational efficiency and profitability compared to the previous year’s margin of 14.4%.

Shareholdings Patterns of Glenmark Pharmaceuticals Ltd 

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters +	46.65%	46.65%	46.65%	46.65%	46.65%
FIIs +	25.51%	24.79%	23.71%	21.38%	20.98%
DIIs +	9.10%	10.31%	10.92%	13.36%	13.93%
Government +	0.04%	0.04%	0.04%	0.04%	0.04%
Public +	18.70%	18.21%	18.70%	18.58%	18.42%
No. of Shareholders	2,36,908	2,32,685	2,09,931	1,99,451	1,92,630

The shareholding patterns for Glenmark Pharmaceuticals Ltd over recent periods:

• Promoters have maintained a stable holding of 46.65% throughout the periods from June 2023 to June 2024.
• Foreign Institutional Investors (FIIs) have seen a gradual decrease in their shareholding from 25.51% in June 2023 to 20.98% by June 2024.
• Domestic Institutional Investors (DIIs) have increased their stake from 9.10% in June 2023 to 13.93% by June 2024.
• Government holdings have remained constant at 0.04% throughout the year.
• Public shareholding has slightly decreased from 18.70% in June 2023 to 18.42% in June 2024.

The total number of shareholders has decreased from 236,908 in June 2023 to 192,630 in June 2024, indicating a reduction in shareholder base over the year.

How to Buy Glenmark Pharmaceuticals Ltd Shares in India?

Below are the trading platforms that you can use to purchase Glenmark Pharmaceuticals Ltd shares:

➤ Zerodha

➤ Upstox

➤ Groww

➤ AngelOne

➤ ICICIDirect

Glenmark Pharmaceuticals Ltd Share Price Prediction: 2024 – 2030

Glenmark Pharmaceuticals Ltd Share Price Target 2024

When	Maximum Price	Minimum Price
August 2024	1,579.75	1,373.70
September 2024	1,642.94	1,428.65
October 2024	1,610.73	1,400.63
November 2024	1,675.16	1,456.66
December 2024	1,691.91	1,471.23

In 2024, Glenmark Pharmaceuticals Ltd is projected to experience fluctuating stock prices. In August 2024, the maximum price is expected to reach ₹1,579.75, with a minimum price of ₹1,373.70. By December 2024, the company’s stock is anticipated to achieve a maximum price of ₹1,691.91 and a minimum price of ₹1,471.23.

Glenmark Pharmaceuticals Ltd Share Price Target 2025

When	Maximum Price	Minimum Price
January 2025	1,708.83	1,314.48
February 2025	1,726.09	1,327.76
March 2025	1,762.34	1,355.64
April 2025	1,744.89	1,342.22
May 2025	1,694.07	1,303.13
June 2025	1,770.30	1,361.77
July 2025	1,735.59	1,335.07
August 2025	1,789.27	1,376.36
September 2025	1,810.74	1,392.88
October 2025	1,857.82	1,429.09
November 2025	1,904.26	1,464.82
December 2025	1,989.95	1,530.73

In 2025, Glenmark Pharmaceuticals Ltd is projected to see its stock prices fluctuate throughout the year. As we step into January, the maximum price is expected to be ₹1,708.83, with a minimum of ₹1,314.48. By December, the stock is anticipated to reach a maximum price of ₹1,989.95 and a minimum of ₹1,530.73.

Glenmark Pharmaceuticals Ltd Share Price Prediction 2026

When	Maximum Price	Minimum Price
January 2026	2,049.65	1,576.66
February 2026	1,998.41	1,537.24
March 2026	2,038.38	1,567.98
April 2026	2,079.98	1,599.98
May 2026	2,059.39	1,584.14
June 2026	2,110.87	1,623.75
July 2026	2,069.48	1,591.91
August 2026	2,133.49	1,641.14
September 2026	2,176.15	1,673.97
October 2026	2,232.73	1,717.49
November 2026	2,288.55	1,760.43
December 2026	2,345.77	1,804.44

Glenmark Pharmaceuticals Ltd Share Price Target 2027

When	Maximum Price	Minimum Price
January 2027	2,369.22	1,822.48
February 2027	2,429.97	1,869.21
March 2027	2,524.74	1,942.11
April 2027	2,475.24	1,904.03
May 2027	2,403.14	1,848.57
June 2027	2,511.29	1,931.76
July 2027	2,462.04	1,893.88
August 2027	2,538.19	1,952.45
September 2027	2,627.03	2,020.79
October 2027	2,695.33	2,073.33
November 2027	2,762.71	2,125.16
December 2027	2,831.78	2,178.29

Glenmark Pharmaceuticals Ltd Share Price Target 2028

When	Maximum Price	Minimum Price
January 2028	2,888.42	2,221.86
February 2028	2,962.48	2,278.83
March 2028	3,078.01	2,367.70
April 2028	3,017.66	2,321.28
May 2028	2,929.77	2,253.67
June 2028	3,061.61	2,355.08
July 2028	3,001.58	2,308.91
August 2028	3,094.41	2,380.31
September 2028	3,202.71	2,463.63
October 2028	3,285.98	2,527.68
November 2028	3,368.13	2,590.87
December 2028	3,452.34	2,655.64

Glenmark Pharmaceuticals Ltd Share Price Prediction 2029

When	Maximum Price	Minimum Price
January 2029	3,521.38	2,708.76
February 2029	3,611.68	2,778.21
March 2029	3,752.53	2,886.56
April 2029	3,678.95	2,829.96
May 2029	3,571.80	2,747.54
June 2029	3,732.53	2,871.18
July 2029	3,659.34	2,814.88
August 2029	3,772.52	2,901.94
September 2029	3,904.56	3,003.50
October 2029	4,006.07	3,081.60
November 2029	4,106.23	3,158.64
December 2029	4,208.88	3,237.60

Glenmark Pharmaceuticals Ltd Share Price Target 2030

When	Maximum Price	Minimum Price
January 2030	4,293.06	3,302.35
February 2030	4,403.14	3,387.03
March 2030	4,574.86	3,519.12
April 2030	4,485.16	3,450.12
May 2030	4,354.52	3,349.63
June 2030	4,550.47	3,500.36
July 2030	4,461.25	3,431.73
August 2030	4,599.23	3,537.87
September 2030	4,760.20	3,661.69
October 2030	4,883.96	3,756.90
November 2030	5,006.06	3,850.82
December 2030	5,131.21	3,947.09

Glenmark Pharmaceuticals Ltd is expected to see a significant rise in its stock prices throughout the year. As we step into January, the maximum price is projected to be ₹4,293.06, with a minimum of ₹3,302.35. By December, the stock is anticipated to peak at ₹5,131.21, while the minimum is expected to be ₹3,947.09.

Glenmark Pharmaceuticals Ltd Financial Condition: Last 5 Years

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales +	10,641	10,944	12,305	12,990	11,813	12,021
Expenses +	8,942	8,860	9,978	10,712	10,618	10,675
Operating Profit	1,699	2,084	2,327	2,278	1,195	1,346
OPM %	16%	19%	19%	18%	10%	11%
Other Income +	191	95	-101	-449	336	265
Interest	377	353	298	350	516	444
Depreciation	417	444	487	611	582	558
Profit before tax	1,096	1,382	1,441	868	434	609
Tax %	29%	30%	31%	57%	430%
Net Profit +	776	970	994	377	-1,434	-1,266
EPS in Rs	27.5	34.38	33.37	10.53	-53.22	-46.46
Dividend Payout %	9%	7%	7%	24%	-5%

The financial performance of Glenmark Pharmaceuticals Ltd has exhibited notable fluctuations over the past five years:

• Sales have generally increased from ₹10,641 crore in March 2020 to ₹12,990 crore in March 2023, but decreased to ₹11,813 crore in March 2024. The trailing twelve months (TTM) sales stand at ₹12,021 crore.
• Expenses have risen steadily, peaking at ₹10,712 crore in March 2023 before slightly declining to ₹10,618 crore in March 2024, with a TTM of ₹10,675 crore.
• Operating Profit has varied, reaching a high of ₹2,327 crore in March 2022 but falling to ₹1,195 crore in March 2024. The operating profit margin (OPM%) has decreased from 16% in March 2020 to 10% in March 2024, with a TTM of 11%.
• Other Income shifted from a positive ₹191 crore in March 2020 to a negative ₹449 crore in March 2023, before recovering to ₹336 crore in March 2024, with a TTM of ₹265 crore.
• Interest expenses have increased from ₹377 crore in March 2020 to ₹516 crore in March 2024, with a TTM of ₹444 crore.
• Depreciation has risen from ₹417 crore in March 2020 to ₹582 crore in March 2024, with a TTM of ₹558 crore.
• Profit Before Tax has seen significant volatility, with a high of ₹1,441 crore in March 2022 and a low of ₹434 crore in March 2024, and a TTM of ₹609 crore.
• Tax Rate has been exceptionally high at 430% in March 2024.
• Net Profit turned negative in March 2024, declining from ₹776 crore in March 2020 to a loss of ₹1,434 crore in March 2024, with a TTM loss of ₹1,266 crore.
• Earnings Per Share (EPS) has similarly deteriorated, from ₹27.5 in March 2020 to a negative ₹53.22 in March 2024, with a TTM EPS of -₹46.46.
• Dividend Payout has varied, from 9% in March 2020 to a negative 5% in March 2024.

Overall, Glenmark Pharmaceuticals Ltd has faced declining profitability and increasing financial strain, with recent figures reflecting significant losses and negative EPS.

FAQs